Haemonetics Financials - Benzinga

Haemonetics Corp

HAENYSE

Trade with Public

Trade with Public

$105.79

0.490.47%

al cierre: Sep 28, 5:00 PM EST

$105.79

N/A

After hour: 4:00 PM EST

Panorámica general Noticias Previsión de beneficios Eventos Precios objetivoFinanzasSentimiento Propiedad Comparar Opciones Informe de acciones

Haemonetics Financials

Haemonetics (HAE) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Haemonetics Q1 Adj. EPS $1.14 Beats $1.08 Estimate, Sales $339.380M Beat $327.894M Estimate

Benzinga Newsdesk

PRO
Haemonetics Widens FY2027 Sales Guidance from $1.410B-$1.427B to $1.401B-$1.441B vs $1.402B Est

Haemonetics (NYSE:HAE) widens FY2027 sales outlook from $1.410 billion-$1.427 billion to $1.401 billion-$1.441 billion vs $1.402 billion estimate.

Benzinga Newsdesk

PRO
Haemonetics Sees FY2027 Adj EPS $5.26-$5.31 vs $5.29 Est; Sees Sales $1.410B-$1.427B vs $1.394B Est

FISCAL 2027 GUIDANCEThe Company issued its fiscal 2027 GAAP total revenueand organic revenue growth guidance as follows: Total CompanyReported Revenue4 - 7%53rd week

Benzinga Newsdesk

PRO
Haemonetics Q4 Adj. EPS $1.29 Beats $1.27 Estimate, Sales $346.351M Beat $336.862M Estimate

Haemonetics (NYSE:HAE) reported quarterly earnings of $1.29 per share which beat the analyst consensus estimate of $1.27 by 1.57 percent. This is a 4.03 percent increase over earnings of $1.24 per share from the same

Benzinga Newsdesk

These Analysts Revise Their Forecasts On Haemonetics After Q3 Earnings

Avi Kapoor

PRO
Haemonetics Sees Revenue for 2026 FY is expected to down by -3 to -1% YoY

Haemonetics (NYSE:HAE) sees Revenue for 2026 FY is expected to down by -3 to -1% YoY

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved